{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T16:43:05Z","timestamp":1790959385096,"version":"4.1.0"},"reference-count":112,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["cell.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Trends in Molecular Medicine"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.molmed.2025.10.010","type":"journal-article","created":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T21:34:26Z","timestamp":1764279266000},"page":"658-677","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["The right drug at the right time: key to IBD success"],"prefix":"10.1016","volume":"32","author":[{"given":"Davide Giuseppe","family":"Ribaldone","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Valdiserra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clelia","family":"Di Salvo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilaria","family":"Puxeddu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Bertani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Antonioli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.molmed.2025.10.010_bb0005","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.3390\/ijms24021526","article-title":"Pathophysiology of inflammatory bowel disease: innate immune system","volume":"24","author":"Saez","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.molmed.2025.10.010_bb0010","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1053\/j.gastro.2022.01.023","article-title":"What does disease progression look like in ulcerative colitis, and how might it be prevented?","volume":"162","author":"Krugliak Cleveland","year":"2022","journal-title":"Gastroenterology"},{"key":"10.1016\/j.molmed.2025.10.010_bb0015","doi-asserted-by":"crossref","first-page":"549","DOI":"10.7861\/clinmed.2023-0493","article-title":"Crohn's disease: an update","volume":"23","author":"Cockburn","year":"2023","journal-title":"Clin. Med."},{"key":"10.1016\/j.molmed.2025.10.010_bb0020","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1016\/j.cell.2019.07.045","article-title":"Therapeutic opportunities in inflammatory bowel disease: mechanistic dissection of host\u2013microbiome relationships","volume":"178","author":"Plichta","year":"2019","journal-title":"Cell"},{"key":"10.1016\/j.molmed.2025.10.010_bb0025","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/j.immuni.2017.04.004","article-title":"Regionalized development and maintenance of the intestinal adaptive immune landscape","volume":"46","author":"Agace","year":"2017","journal-title":"Immunity"},{"key":"10.1016\/j.molmed.2025.10.010_bb0030","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.jcmgh.2021.03.012","article-title":"Deep analysis of the peripheral immune system in IBD reveals new insight in disease subtyping and response to monotherapy or combination therapy","volume":"12","author":"Kosoy","year":"2021","journal-title":"Cell. Mol. Gastroenterol. Hepatol."},{"key":"10.1016\/j.molmed.2025.10.010_bb0035","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.1038\/s41590-024-01994-8","article-title":"A longitudinal single-cell atlas of anti-tumour necrosis factor treatment in inflammatory bowel disease","volume":"25","author":"Thomas","year":"2024","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.molmed.2025.10.010_bb0040","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1136\/gutjnl-2011-301668","article-title":"Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial","volume":"61","author":"Hueber","year":"2012","journal-title":"Gut"},{"key":"10.1016\/j.molmed.2025.10.010_bb0045","doi-asserted-by":"crossref","first-page":"825","DOI":"10.3390\/cells14110825","article-title":"Innate lymphoid cells in inflammatory bowel disease","volume":"14","author":"Yao","year":"2025","journal-title":"Cells"},{"key":"10.1016\/j.molmed.2025.10.010_bb0050","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1038\/s41577-024-01008-6","article-title":"Strategies for targeting cytokines in inflammatory bowel disease","volume":"24","author":"Neurath","year":"2024","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.molmed.2025.10.010_bb0055","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1038\/s41575-024-01035-7","article-title":"Understanding the therapeutic toolkit for inflammatory bowel disease","volume":"22","author":"Vieujean","year":"2025","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.molmed.2025.10.010_bb0060","article-title":"Treatment of inflammatory bowel disease: a comprehensive review","volume":"8","author":"Cai","year":"2021","journal-title":"Front. Med."},{"key":"10.1016\/j.molmed.2025.10.010_bb0065","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.3390\/ph16091272","article-title":"Pharmacological therapy in inflammatory bowel diseases: a narrative review of the past 90 years","volume":"16","author":"Imbrizi","year":"2023","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.molmed.2025.10.010_bb0070","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1111\/apt.15685","article-title":"Systematic review and meta-analysis: efficacy and safety of early biologic treatment in adult and paediatric patients with Crohn's disease","volume":"51","author":"Ungaro","year":"2020","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.molmed.2025.10.010_bb0075","doi-asserted-by":"crossref","first-page":"2249","DOI":"10.3390\/biomedicines11082249","article-title":"Inflammatory bowel disease: emerging therapies and future treatment strategies","volume":"11","author":"Bretto","year":"2023","journal-title":"Biomedicines"},{"key":"10.1016\/j.molmed.2025.10.010_bb0080","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.3390\/jcm12041630","article-title":"Past, present and (foreseeable) future of biological anti-TNF alpha therapy","volume":"12","author":"Leone","year":"2023","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.molmed.2025.10.010_bb0085","doi-asserted-by":"crossref","DOI":"10.1111\/imr.13433","article-title":"The integrin receptors: from discovery to structure to medicines","volume":"329","author":"Arnaout","year":"2025","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.molmed.2025.10.010_bb0090","doi-asserted-by":"crossref","first-page":"333","DOI":"10.2147\/CEG.S293272","article-title":"Anti-integrins for the treatment of inflammatory bowel disease: current evidence and perspectives","volume":"14","author":"Gubatan","year":"2021","journal-title":"Clin. Exp. Gastroenterol."},{"key":"10.1016\/j.molmed.2025.10.010_bb0095","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.612830","article-title":"Vedolizumab: potential mechanisms of action for reducing pathological inflammation in inflammatory bowel diseases","volume":"9","author":"Luzentales-Simpson","year":"2021","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.molmed.2025.10.010_bb0100","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1111\/apt.17277","article-title":"Real world population pharmacokinetic study in children and young adults with inflammatory bowel disease discovers novel blood and stool microbial predictors of vedolizumab clearance","volume":"57","author":"Colman","year":"2023","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.molmed.2025.10.010_bb0105","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1080\/14740338.2023.2247976","article-title":"An update on the safety of long-term vedolizumab use in inflammatory bowel disease","volume":"22","author":"Honap","year":"2023","journal-title":"Expert Opin. Drug Saf."},{"key":"10.1016\/j.molmed.2025.10.010_bb0110","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1038\/s41575-023-00768-1","article-title":"IL-12 and IL-23 pathway inhibition in inflammatory bowel disease","volume":"20","author":"Verstockt","year":"2023","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.molmed.2025.10.010_bb2005","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1016\/j.clinthera.2022.08.010","article-title":"Population pharmacokinetics and exposure-response analyses of ustekinumab in patients with moderately to severely active Crohn's disease","volume":"44","author":"Adedokun","year":"2022","journal-title":"Clin. Ther."},{"key":"10.1016\/j.molmed.2025.10.010_bb0115","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.3390\/cells12131730","article-title":"Novel small molecules in IBD: current state and future perspectives","volume":"12","author":"Jefremow","year":"2023","journal-title":"Cells"},{"key":"10.1016\/j.molmed.2025.10.010_bb0120","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1007\/s00011-021-01482-x","article-title":"Targeting JAK\/STAT signaling pathways in treatment of inflammatory bowel disease","volume":"70","author":"Wang","year":"2021","journal-title":"Inflamm. Res."},{"key":"10.1016\/j.molmed.2025.10.010_bb0125","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cytogfr.2024.07.008","article-title":"Therapeutic inhibition of the JAK-STAT pathway in the treatment of inflammatory bowel disease","volume":"79","author":"Chen","year":"2024","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.molmed.2025.10.010_bb0130","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1241954","article-title":"Risk of herpes zoster associated with JAK inhibitors in immune-mediated inflammatory diseases: a systematic review and network meta-analysis","volume":"14","author":"Xu","year":"2023","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.molmed.2025.10.010_bb0135","doi-asserted-by":"crossref","DOI":"10.1080\/07853890.2025.2594267","article-title":"Cardiovascular safety of Janus kinase inhibitors in inflammatory bowel disease: a systematic review and network meta-analysis","volume":"57","author":"Yang","year":"2025","journal-title":"Ann. Med."},{"key":"10.1016\/j.molmed.2025.10.010_bb0140","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1038\/s41575-021-00574-7","article-title":"Sphingosine 1-phosphate modulation and immune cell trafficking in inflammatory bowel disease","volume":"19","author":"Verstockt","year":"2022","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.molmed.2025.10.010_bb0145","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2147\/PROM.S122401","article-title":"Long-term safety and real-world effectiveness of fingolimod in relapsing multiple sclerosis","volume":"9","author":"Druart","year":"2018","journal-title":"Patient Relat. Outcome Meas."},{"key":"10.1016\/j.molmed.2025.10.010_bb0150","doi-asserted-by":"crossref","first-page":"2641","DOI":"10.1002\/1873-3468.14973","article-title":"Sphingosine-1-phosphate signalling in the heart: exploring emerging perspectives in cardiopathology","volume":"598","author":"Phan","year":"2024","journal-title":"FEBS Lett."},{"key":"10.1016\/j.molmed.2025.10.010_bb0155","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1111\/apt.17509","article-title":"Review article: risk of cardiovascular events in patients with inflammatory bowel disease receiving small molecule drugs","volume":"57","author":"Olivera","year":"2023","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.molmed.2025.10.010_bb0160","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1056\/NEJMoa1513248","article-title":"Ozanimod induction and maintenance treatment for ulcerative colitis","volume":"374","author":"Sandborn","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.molmed.2025.10.010_bb0165","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1056\/NEJMoa2033617","article-title":"Ozanimod as induction and maintenance therapy for ulcerative colitis","volume":"385","author":"Sandborn","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.molmed.2025.10.010_bb0170","doi-asserted-by":"crossref","DOI":"10.1093\/ecco-jcc\/jjae173","article-title":"Low incidence of macular edema and other ocular events in the Etrasimod development program","volume":"19","author":"Dubinsky","year":"2025","journal-title":"J. Crohn's Colitis"},{"key":"10.1016\/j.molmed.2025.10.010_bb0175","doi-asserted-by":"crossref","first-page":"3475","DOI":"10.3390\/jcm14103475","article-title":"The current sphingosine 1 phosphate receptor modulators in the management of ulcerative colitis","volume":"14","author":"Choon","year":"2025","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.molmed.2025.10.010_bb0180","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1093\/ecco-jcc\/jjab178","article-title":"ECCO guidelines on therapeutics in ulcerative colitis: medical treatment","volume":"16","author":"Raine","year":"2022","journal-title":"J. Crohn's Colitis"},{"key":"10.1016\/j.molmed.2025.10.010_bb0185","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1053\/j.gastro.2024.10.001","article-title":"AGA living clinical practice guideline on pharmacological management of moderate-to-severe ulcerative colitis","volume":"167","author":"Singh","year":"2024","journal-title":"Gastroenterology"},{"key":"10.1016\/j.molmed.2025.10.010_bb0190","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1093\/ecco-jcc\/jjae091","article-title":"ECCO guidelines on therapeutics in Crohn's disease: medical treatment","volume":"18","author":"Gordon","year":"2024","journal-title":"J. Crohn's Colitis"},{"key":"10.1016\/j.molmed.2025.10.010_bb0195","doi-asserted-by":"crossref","first-page":"203","DOI":"10.2147\/CLEP.S150030","article-title":"Population-based cohort study on comparative effectiveness and safety of biologics in inflammatory bowel disease","volume":"10","author":"Di Domenicantonio","year":"2018","journal-title":"Clin. Epidemiol."},{"key":"10.1016\/j.molmed.2025.10.010_bb0200","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa2314585","article-title":"Risankizumab versus ustekinumab for moderate-to-severe Crohn\u2019s disease","volume":"391","author":"Peyrin-Biroulet","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.molmed.2025.10.010_bb0205","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1001\/jama.2023.1084","article-title":"Effect of induction therapy with olamkicept vs placebo on clinical response in patients with active ulcerative colitis: a randomized clinical trial","volume":"329","author":"Zhang","year":"2023","journal-title":"Jama"},{"key":"10.1016\/j.molmed.2025.10.010_bb0210","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1056\/NEJM199905063401804","article-title":"Infliximab for the treatment of fistulas in patients with Crohn's disease","volume":"340","author":"Present","year":"1999","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.molmed.2025.10.010_bb0215","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1080\/14740338.2023.2278686","article-title":"Ustekinumab as induction and maintenance therapy for ulcerative colitis \u2013 national extended follow-up and a review of the literature","volume":"23","author":"Chetwood","year":"2024","journal-title":"Expert Opin. Drug Saf."},{"key":"10.1016\/j.molmed.2025.10.010_bb0220","doi-asserted-by":"crossref","first-page":"6173","DOI":"10.3390\/jcm11206173","article-title":"Therapeutic drug monitoring of subcutaneous infliximab in inflammatory bowel disease-understanding pharmacokinetics and exposure response relationships in a new era of subcutaneous biologics","volume":"11","author":"Little","year":"2022","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.molmed.2025.10.010_bb0225","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1016\/j.cgh.2018.09.033","article-title":"Combination therapy with infliximab and azathioprine improves infliximab pharmacokinetic features and efficacy: a post hoc analysis","volume":"17","author":"Colombel","year":"2019","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.molmed.2025.10.010_bb0230","doi-asserted-by":"crossref","first-page":"2597","DOI":"10.3748\/wjg.v28.i23.2597","article-title":"Higher infliximab and adalimumab trough levels are associated with fistula healing in patients with fistulising perianal Crohn's disease","volume":"28","author":"Gu","year":"2022","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.molmed.2025.10.010_bb0235","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.dld.2017.01.141","article-title":"Safety of treatments for inflammatory bowel disease: Clinical practice guidelines of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD)","volume":"49","author":"Biancone","year":"2017","journal-title":"Dig. Liver Dis."},{"key":"10.1016\/j.molmed.2025.10.010_bb0240","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1016\/j.cgh.2024.08.032","article-title":"Efficacy and safety of upadacitinib for perianal fistulizing Crohn\u2019s disease: a post hoc analysis of 3 phase 3 trials","volume":"23","author":"Colombel","year":"2025","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.molmed.2025.10.010_bb0245","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.4240\/wjgs.v16.i5.1235","article-title":"Surgical treatment of inflammatory bowel disease: from the gastroenterologist's stand-point","volume":"16","author":"Triantafillidis","year":"2024","journal-title":"World J. Gastrointest. Surg."},{"key":"10.1016\/j.molmed.2025.10.010_bb0250","doi-asserted-by":"crossref","first-page":"3229","DOI":"10.3390\/biomedicines11123229","article-title":"A narrative review of cytokine networks: pathophysiological and therapeutic implications for inflammatory bowel disease pathogenesis","volume":"11","author":"Vebr","year":"2023","journal-title":"Biomedicines"},{"key":"10.1016\/j.molmed.2025.10.010_bb0255","doi-asserted-by":"crossref","first-page":"s1","DOI":"10.1136\/gutjnl-2024-334395","article-title":"British Society of Gastroenterology guidelines on inflammatory bowel disease in adults: 2025","volume":"74","author":"Moran","year":"2025","journal-title":"Gut"},{"key":"10.1016\/j.molmed.2025.10.010_bb0260","doi-asserted-by":"crossref","DOI":"10.1177\/17562848231159452","article-title":"Is there an optimal sequence of biologic therapies for inflammatory bowel disease?","volume":"16","author":"Bressler","year":"2023","journal-title":"Ther. Adv. Gastroenterol."},{"key":"10.1016\/j.molmed.2025.10.010_bb0265","doi-asserted-by":"crossref","first-page":"2681","DOI":"10.1093\/ibd\/izaf036","article-title":"Efficacy and safety of etrasimod in patients with moderately to severely active ulcerative colitis stratified by baseline modified mayo score: a post hoc analysis from the phase 3 ELEVATE UC Clinical Program","volume":"31","author":"Sands","year":"2025","journal-title":"Inflamm. Bowel Dis."},{"key":"10.1016\/j.molmed.2025.10.010_bb0270","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1093\/ecco-jcc\/jjad169","article-title":"Tofacitinib for patients with anti-TNF refractory ulcerative proctitis: a multicentre cohort study from the GETAID","volume":"18","author":"Uzzan","year":"2024","journal-title":"J. Crohn's Colitis"},{"key":"10.1016\/j.molmed.2025.10.010_bb0275","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1016\/S0140-6736(15)00068-9","article-title":"Early combined immunosuppression for the management of Crohn's disease (REACT): a cluster randomised controlled trial","volume":"386","author":"Khanna","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.molmed.2025.10.010_bb0280","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1056\/NEJMc1915739","article-title":"Vedolizumab versus adalimumab for moderate-to-severe ulcerative colitis","volume":"382","author":"O'Connor","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.molmed.2025.10.010_bb0285","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1016\/j.dld.2020.06.014","article-title":"A propensity score weighted comparison of vedolizumab, adalimumab, and golimumab in patients with ulcerative colitis","volume":"52","author":"Macaluso","year":"2020","journal-title":"Dig. Liver Dis."},{"key":"10.1016\/j.molmed.2025.10.010_bb0290","doi-asserted-by":"crossref","first-page":"ii64","DOI":"10.1093\/ecco-jcc\/jjab185","article-title":"Blockade of IL-23: what is in the pipeline?","volume":"16","author":"Parigi","year":"2022","journal-title":"J. Crohn's Colitis"},{"key":"10.1016\/j.molmed.2025.10.010_bb0295","article-title":"Mirikizumab improves quality of life in patients with moderately-to-severely active ulcerative colitis: results from the phase 3 LUCENT-1 induction and LUCENT-2 maintenance studies","volume":"360 5","author":"Sands","year":"2023","journal-title":"Crohn's Colitis"},{"key":"10.1016\/j.molmed.2025.10.010_bb0300","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1136\/gutjnl-2019-318264","article-title":"Anti-TNF therapy in IBD exerts its therapeutic effect through macrophage IL-10 signalling","volume":"69","author":"Koelink","year":"2020","journal-title":"Gut"},{"key":"10.1016\/j.molmed.2025.10.010_bb0305","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1016\/j.cgh.2019.03.037","article-title":"Appropriate therapeutic drug monitoring of biologic agents for patients with inflammatory bowel diseases","volume":"17","author":"Papamichael","year":"2019","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.molmed.2025.10.010_bb0310","doi-asserted-by":"crossref","first-page":"824","DOI":"10.3390\/biomedicines12040824","article-title":"Therapeutic drug monitoring as a tool for the clinical outcome prediction in vedolizumab-treated patients: an Italian pilot study","volume":"12","author":"Cusato","year":"2024","journal-title":"Biomedicines"},{"key":"10.1016\/j.molmed.2025.10.010_bb0315","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1111\/1751-2980.13264","article-title":"Therapeutic drug monitoring in patients with inflammatory bowel disease on ustekinumab","volume":"25","author":"Saleh","year":"2024","journal-title":"J. Dig. Dis."},{"key":"10.1016\/j.molmed.2025.10.010_bb0320","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1097\/MCG.0000000000001396","article-title":"Therapeutic drug monitoring for current and investigational inflammatory bowel disease treatments","volume":"55","author":"Lee","year":"2021","journal-title":"J. Clin. Gastroenterol."},{"key":"10.1016\/j.molmed.2025.10.010_bb0325","doi-asserted-by":"crossref","DOI":"10.1177\/17562848241251600","article-title":"Biomarkers in inflammatory bowel disease: a practical guide","volume":"17","author":"Clough","year":"2024","journal-title":"Ther. Adv. Gastroenterol."},{"key":"10.1016\/j.molmed.2025.10.010_bb0330","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1016\/j.cgh.2024.01.026","article-title":"Biomarkers for personalizing IBD therapy: the quest continues","volume":"22","author":"Atreya","year":"2024","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.molmed.2025.10.010_bb0335","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1136\/flgastro-2021-101827","article-title":"Management of Crohn's stricture: medical, endoscopic and surgical therapies","volume":"13","author":"Ismail","year":"2022","journal-title":"Frontline Gastroenterol."},{"key":"10.1016\/j.molmed.2025.10.010_bb0340","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.861790","article-title":"Immune cell landscaping reveals distinct immune signatures of inflammatory bowel disease","volume":"13","author":"Bai","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.molmed.2025.10.010_bb0345","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2022.896591","article-title":"The role of tissue-resident macrophages in the development and treatment of inflammatory bowel disease","volume":"10","author":"Ma","year":"2022","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.molmed.2025.10.010_bb0350","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1084\/jem.186.10.1749","article-title":"Suppressive role of B cells in chronic colitis of T cell receptor alpha mutant mice","volume":"186","author":"Mizoguchi","year":"1997","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.molmed.2025.10.010_bb0355","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1053\/gast.2002.30308","article-title":"Distinct inflammatory mechanisms mediate early versus late colitis in mice","volume":"122","author":"Spencer","year":"2002","journal-title":"Gastroenterology"},{"key":"10.1016\/j.molmed.2025.10.010_bb0360","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1053\/j.gastro.2004.11.053","article-title":"Proinflammatory effects of TH2 cytokines in a murine model of chronic small intestinal inflammation","volume":"128","author":"Bamias","year":"2005","journal-title":"Gastroenterology"},{"key":"10.1016\/j.molmed.2025.10.010_bb0365","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1002\/ibd.20375","article-title":"Early molecular and functional changes in colonic epithelium that precede increased gut permeability during colitis development in Mdr1a\u2212\/\u2212 mice","volume":"14","author":"Collett","year":"2008","journal-title":"Inflamm. Bowel Dis."},{"key":"10.1016\/j.molmed.2025.10.010_bb0370","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1002\/ibd.20986","article-title":"Ulcerative colitis: correlation of the Rachmilewitz endoscopic activity index with fecal calprotectin, clinical activity, C-reactive protein, and blood leukocytes","volume":"15","author":"Schoepfer","year":"2009","journal-title":"Inflamm. Bowel Dis."},{"key":"10.1016\/j.molmed.2025.10.010_bb0375","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/1471-230X-12-97","article-title":"Deletion of Foxp3+ regulatory T cells in genetically targeted mice supports development of intestinal inflammation","volume":"12","author":"Boehm","year":"2012","journal-title":"BMC Gastroenterol."},{"key":"10.1016\/j.molmed.2025.10.010_bb0380","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1093\/ecco-jcc\/jjz072","article-title":"Mucosal and systemic Immune profiles differ during early and late phases of the disease in patients with active ulcerative colitis","volume":"13","author":"Mavroudis","year":"2019","journal-title":"J. Crohn's Colitis"},{"key":"10.1016\/j.molmed.2025.10.010_bb0385","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2021.103017","article-title":"The influence of cytokines on the complex pathology of ulcerative colitis","volume":"21","author":"Nakase","year":"2022","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.molmed.2025.10.010_bb0390","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.immuni.2019.06.008","article-title":"Temporally distinct functions of the cytokines IL-12 and IL-23 drive chronic colon inflammation in response to intestinal barrier impairment","volume":"51","author":"Eftychi","year":"2019","journal-title":"Immunity"},{"key":"10.1016\/j.molmed.2025.10.010_bb0395","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0054562","article-title":"Distinct profiles of effector cytokines mark the different phases of Crohn's disease","volume":"8","author":"Zorzi","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.molmed.2025.10.010_bb0400","doi-asserted-by":"crossref","first-page":"391","DOI":"10.3390\/biomedicines13020391","article-title":"Early ustekinumab use improves clinical outcomes in biologic-naive Crohn's disease patients: a retrospective multicenter cohort study in Taiwan","volume":"13","author":"Chang","year":"2025","journal-title":"Biomedicines"},{"key":"10.1016\/j.molmed.2025.10.010_bb0405","first-page":"385","article-title":"Role of cytokines in the early stages of chronic colitis in TCR alpha-mutant mice","volume":"76","author":"Mizoguchi","year":"1997","journal-title":"Lab. Invest. J. Tech. Methods Pathol."},{"key":"10.1016\/j.molmed.2025.10.010_bb0410","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.691480","article-title":"Glucocorticoid therapy in inflammatory bowel disease: mechanisms and clinical practice","volume":"12","author":"Bruscoli","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.molmed.2025.10.010_bb0415","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1111\/apt.17039","article-title":"Sources of excess steroid prescriptions and clinical adverse outcomes associated with steroid excess in patients with inflammatory bowel disease: the Leeds IBD Steroids Study","volume":"56","author":"Rosiou","year":"2022","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.molmed.2025.10.010_bb0420","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1016\/j.cgh.2025.05.019","article-title":"Appropriate use and complications of corticosteroids in inflammatory bowel disease: a comprehensive review","volume":"23","author":"Feuerstein","year":"2025","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.molmed.2025.10.010_bb0425","doi-asserted-by":"crossref","first-page":"4678","DOI":"10.3390\/jcm13164678","article-title":"Safety and effectiveness of thiopurines and small molecules in elderly patients with inflammatory bowel diseases","volume":"13","author":"Strigac","year":"2024","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.molmed.2025.10.010_bb0430","doi-asserted-by":"crossref","first-page":"11","DOI":"10.5217\/ir.2020.00155","article-title":"Use of thiopurines in inflammatory bowel disease: an update","volume":"20","author":"Singh","year":"2022","journal-title":"Intest. Res."},{"key":"10.1016\/j.molmed.2025.10.010_bb0435","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2021.681907","article-title":"Thiopurines in inflammatory bowel disease. How to optimize thiopurines in the biologic era?","volume":"8","author":"Gargallo-Puyuelo","year":"2021","journal-title":"Front. Med."},{"key":"10.1016\/j.molmed.2025.10.010_bb0440","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/nrrheum.2010.5","article-title":"Methotrexate \u2013 how does it really work?","volume":"6","author":"Chan","year":"2010","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.molmed.2025.10.010_bb0445","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.tips.2021.10.010","article-title":"Adenosine and inflammation: it's time to (re)solve the problem","volume":"43","author":"Antonioli","year":"2022","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.molmed.2025.10.010_bb0450","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1111\/apt.18194","article-title":"Systematic review: methotrexate \u2013 a poorly understood and underused medication in inflammatory bowel disease","volume":"60","author":"Sequier","year":"2024","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.molmed.2025.10.010_bb0455","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1097\/FTD.0000000000000849","article-title":"Adalimumab concentration changes after dose escalation in inflammatory bowel disease","volume":"43","author":"Jasurda","year":"2021","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.molmed.2025.10.010_bb0460","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.cyto.2016.08.014","article-title":"Molecular mechanisms of action of anti-TNF-alpha agents \u2013 comparison among therapeutic TNF-alpha antagonists","volume":"101","author":"Mitoma","year":"2018","journal-title":"Cytokine"},{"key":"10.1016\/j.molmed.2025.10.010_bb0465","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1080\/17425255.2017.1258401","article-title":"Evaluation of the pharmacokinetics, pharmacodynamics and clinical efficacy of empagliflozin for the treatment of type 2 diabetes","volume":"13","author":"Tomlinson","year":"2017","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"10.1016\/j.molmed.2025.10.010_bb0470","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1604337","article-title":"Commentary: guselkumab binding to CD64+ IL-23-producing myeloid cells enhances potency for neutralizing IL-23 signaling","volume":"16","author":"Valdiserra","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.molmed.2025.10.010_bb0475","doi-asserted-by":"crossref","DOI":"10.1016\/j.medj.2025.100605","article-title":"Guselkumab in moderately to severely active ulcerative colitis: another interleukin-23p19 subunit inhibitor or more?","volume":"6","author":"Orlando","year":"2025","journal-title":"Med"},{"key":"10.1016\/j.molmed.2025.10.010_bb0480","doi-asserted-by":"crossref","DOI":"10.1093\/ecco-jcc\/jjaf144","article-title":"Practical considerations for the use of IL-23p19 inhibitors in inflammatory bowel disease: how to choose between them and why it matters?","volume":"19","author":"Pugliano","year":"2025","journal-title":"J. Crohn's Colitis"},{"key":"10.1016\/j.molmed.2025.10.010_bb0485","doi-asserted-by":"crossref","DOI":"10.1111\/cts.13688","article-title":"Upadacitinib: Mechanism of action, clinical, and translational science","volume":"17","author":"Mohamed","year":"2024","journal-title":"Clin. Translat. Sci."},{"key":"10.1016\/j.molmed.2025.10.010_bb0490","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/S2468-1253(20)30188-6","article-title":"Ozanimod induction therapy for patients with moderate to severe Crohn's disease: a single-arm, phase 2, prospective observer-blinded endpoint study","volume":"5","author":"Feagan","year":"2020","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"10.1016\/j.molmed.2025.10.010_bb0495","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1080\/17425255.2024.2402931","article-title":"Pharmacokinetics of S1P receptor modulators in the treatment of ulcerative colitis","volume":"20","author":"Vieujean","year":"2024","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"10.1016\/j.molmed.2025.10.010_bb0500","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1038\/ajg.2015.120","article-title":"C-reactive protein, fecal calprotectin, and stool lactoferrin for detection of endoscopic activity in symptomatic inflammatory bowel disease patients: a systematic review and meta-analysis","volume":"110","author":"Mosli","year":"2015","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.molmed.2025.10.010_bb0505","doi-asserted-by":"crossref","DOI":"10.14309\/ctg.0000000000000174","article-title":"Fecal dalprotectin predicts mucosal healing in patients with ulcerative colitis treated with biological therapies: a prospective study","volume":"11","author":"Bertani","year":"2020","journal-title":"Clin. Transl. Gastroenterol."},{"key":"10.1016\/j.molmed.2025.10.010_bb0510","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.3390\/biomedicines12071520","article-title":"Precision medicine in inflammatory bowel disease: a spotlight on emerging molecular biomarkers","volume":"12","author":"Mestrovic","year":"2024","journal-title":"Biomedicines"},{"key":"10.1016\/j.molmed.2025.10.010_bb0515","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.1053\/j.gastro.2021.02.019","article-title":"Identification of an anti-integrin alphavbeta6 autoantibody in patients with ulcerative colitis","volume":"160","author":"Kuwada","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1016\/j.molmed.2025.10.010_bb0520","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1038\/s41467-018-03323-8","article-title":"A loop region of BAFF controls B cell survival and regulates recognition by different inhibitors","volume":"9","author":"Vigolo","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.molmed.2025.10.010_bb0525","first-page":"936","article-title":"Differential expression of serum microRNAs in glucocorticoid-resistant patients with ulcerative colitis","volume":"11","author":"Luo","year":"2018","journal-title":"Int. J. Clin. Exp. Pathol."},{"key":"10.1016\/j.molmed.2025.10.010_bb0530","doi-asserted-by":"crossref","first-page":"16205","DOI":"10.1038\/s41598-021-95761-6","article-title":"Comparison between prostaglandin E-major urinary metabolite and C-reactive protein levels to reflect endoscopic scores in patients with ulcerative colitis","volume":"11","author":"Ishida","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.molmed.2025.10.010_bb0535","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1038\/nm.4307","article-title":"Oncostatin M drives intestinal inflammation and predicts response to tumor necrosis factor-neutralizing therapy in patients with inflammatory bowel disease","volume":"23","author":"West","year":"2017","journal-title":"Nat. Med."},{"key":"10.1016\/j.molmed.2025.10.010_bb0540","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1053\/j.gastro.2022.12.042","article-title":"Anti-integrin alphavbeta6 autoantibodies are a novel biomarker that antedate ulcerative colitis","volume":"164","author":"Livanos","year":"2023","journal-title":"Gastroenterology"},{"key":"10.1016\/j.molmed.2025.10.010_bb0545","doi-asserted-by":"crossref","first-page":"45","DOI":"10.3390\/diagnostics12010045","article-title":"Role of B-cell activating factor (BAFF) in inflammatory bowel disease","volume":"12","author":"Kumric","year":"2021","journal-title":"Diagnostics (Basel)"},{"key":"10.1016\/j.molmed.2025.10.010_bb0550","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1331217","article-title":"IL-23 past, present, and future: a roadmap to advancing IL-23 science and therapy","volume":"15","author":"Krueger","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.molmed.2025.10.010_bb0555","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1038\/s41575-020-0273-0","article-title":"JAK-STAT pathway targeting for the treatment of inflammatory bowel disease","volume":"17","author":"Salas","year":"2020","journal-title":"Nat. Rev. Gastroenterol. Hepatol."}],"container-title":["Trends in Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471491425002643?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471491425002643?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T15:00:17Z","timestamp":1783522817000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1471491425002643"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":112,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S1471491425002643"],"URL":"https:\/\/doi.org\/10.1016\/j.molmed.2025.10.010","relation":{},"ISSN":["1471-4914"],"issn-type":[{"value":"1471-4914","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The right drug at the right time: key to IBD success","name":"articletitle","label":"Article Title"},{"value":"Trends in Molecular Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.molmed.2025.10.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}